Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients
Kosh Agarwal, Nezam H. Afdhal, Carla S. Coffin, Scott Fung, Geoffrey Dusheiko, Graham R. Foster, Magdy Elkhashab, Edward Tam, Alnoor Ramji, Radhakrishnan P. Iyer, Patrick Kennedy
Topics & Concepts
ToxicityNucleosideMedicineNucleoside analoguePhase (matter)VirologyPharmacologyGastroenterologyInternal medicineChemistryBiochemistryOrganic chemistryHepatitis B Virus StudiesHepatitis C virus researchDiabetes and associated disorders